Home >> Signaling Pathways >> MAPK Signaling

MAPK Signaling

Targets for  MAPK Signaling

Products for  MAPK Signaling

  1. Cat.No. Product Name Information
  2. GC36652 MPT0B392 MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line. MPT0B392  Chemical Structure
  3. GC64292 MS432 MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively. MS432  Chemical Structure
  4. GC65297 MW-150 MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150  Chemical Structure
  5. GC34918 MW-150 dihydrochloride dihydrate MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 dihydrochloride dihydrate  Chemical Structure
  6. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide  Chemical Structure
  7. GC60262 N-Feruloyloctopamine N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases thephosphorylationlevels of Akt and p38MAPK. N-Feruloyloctopamine  Chemical Structure
  8. GC19260 NCB-0846 NCB-0846 is an orally available TNIK inhibitor with an IC50 of 21 nM. NCB-0846  Chemical Structure
  9. GC69543 NecroIr1

    NecroIr1 is an iridium (III) complex that induces necrosis in cisplatin-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 can activate receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), regulating CDK4 expression.

    NecroIr1  Chemical Structure
  10. GC69544 NecroIr2

    NecroIr2 is an iridium (III) complex that induces necrosis in cisplatin-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 can activate receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), regulating CDK4 expression.

    NecroIr2  Chemical Structure
  11. GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1 NG 25 (hydrochloride hydrate)  Chemical Structure
  12. GC13514 NG25 An inhibitor of MAP4K2 and TAK1 NG25  Chemical Structure
  13. GC17577 NQDI 1 A selective inhibitor of ASK1 NQDI 1  Chemical Structure
  14. GC10069 NSC 23766 trihydrochloride Selective inhibitor of Rac1-GEF interaction. NSC 23766 trihydrochloride  Chemical Structure
  15. GC49186 O-Demethyl Apremilast An active metabolite of apremilast O-Demethyl Apremilast  Chemical Structure
  16. GC18951 Obscurolide A1 Obscurolide A1 is a natural butyrolactone isolated from S. Obscurolide A1  Chemical Structure
  17. GC48652 Olomoucine II A CDK inhibitor Olomoucine II  Chemical Structure
  18. GC33857 Omtriptolide Omtriptolide (PG490-88) is a derivative prodrug of triptolide purified from the Chinese herb. Omtriptolide  Chemical Structure
  19. GC50316 Org 48762-0 Selective p38α/β inhibitor; orally bioavailable Org 48762-0  Chemical Structure
  20. GC12304 OTS514

    TOPK inhibitor,highly potent

    OTS514  Chemical Structure
  21. GC16511 OTS964 OTS964 is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM. OTS964  Chemical Structure
  22. GC69639 OVA-E1 peptide TFA

    OVA-E1 peptide TFA is an antagonist mutant of SIINFEKL [OVA (257-264)]. OVA-E1 peptide activates the p38 and JNK cascades in both mutant and wild-type thymocytes.

    OVA-E1 peptide TFA  Chemical Structure
  23. GC44530 p38 MAPK Inhibitor p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). p38 MAPK Inhibitor  Chemical Structure
  24. GC18602 p38 MAPK Inhibitor IV p38 MAPK Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC50s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively. p38 MAPK Inhibitor IV  Chemical Structure
  25. GC33008 p38 MAPK-IN-1 p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1  Chemical Structure
  26. GC30609 p38 MAPK-IN-2 p38 MAPK-IN-2 is an inhibitor of p38 kinase. p38 MAPK-IN-2  Chemical Structure
  27. GC62404 p38α inhibitor 2 p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2  Chemical Structure
  28. GC31988 p38α inhibitor 1 p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1. p38α inhibitor 1  Chemical Structure
  29. GC30158 p38-α MAPK-IN-1 p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay. p38-α MAPK-IN-1  Chemical Structure
  30. GN10752 Pachymic acid Pachymic acid  Chemical Structure
  31. GC15814 Pamapimod (R-1503, Ro4402257) Pamapimod (R-1503, Ro4402257) (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod (R-1503, Ro4402257)  Chemical Structure
  32. GC36855 Paris saponin VII Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia. Paris saponin VII  Chemical Structure
  33. GC17737 PD 169316 P38 MAPK inhibitor PD 169316  Chemical Structure
  34. GC15646 PD 184161 MEK1/2 inhibitor PD 184161  Chemical Structure
  35. GC17964 PD 198306 MEK1/2 inhibitor PD 198306  Chemical Structure
  36. GC17485 PD 334581 MEK1 inhibitor PD 334581  Chemical Structure
  37. GC10397 PD0325901

    A MEK inhibitor that sustains stem cell renewal

    PD0325901  Chemical Structure
  38. GC63554 PD0325901-O-C2-dioxolane PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader. PD0325901-O-C2-dioxolane  Chemical Structure
  39. GC12989 PD184352 (CI-1040) PD184352 (CI-1040) (PD 184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC50 of 17 nM for MEK1. PD184352 (CI-1040)  Chemical Structure
  40. GC10110 PD318088 Allosteric MEK1/2 inhibitor, non-ATP competitive PD318088  Chemical Structure
  41. GC12819 PD98059

    PD98059 is a potent and selective MEK inhibitor with an IC50 of 2 μM.

    PD98059  Chemical Structure
  42. GC47931 PDE4B Inhibitor A PDE4B inhibitor PDE4B Inhibitor  Chemical Structure
  43. GC44587 PDMP (hydrochloride) PDMP is a ceramide analog first prepared in a search for inhibitors of glucosylceramide synthase. PDMP (hydrochloride)  Chemical Structure
  44. GC11857 Pexmetinib (ARRY-614) Pexmetinib (ARRY-614) is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia. Pexmetinib (ARRY-614)  Chemical Structure
  45. GC50252 PF 06260933 dihydrochloride MAP4K4 (HGK) inhibitor; also inhibits MINK and TNIK PF 06260933 dihydrochloride  Chemical Structure
  46. GC14938 PF-03394197(Oclacitinib) Novel Janus kinase inhibitor PF-03394197(Oclacitinib)  Chemical Structure
  47. GC15821 PF-04880594 RAF inhibitor PF-04880594  Chemical Structure
  48. GC63144 PF-05381941 PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC50s of 156 and186 nM, respectively. PF-05381941  Chemical Structure
  49. GC31675 PF-06260933 PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively. PF-06260933  Chemical Structure
  50. GC14645 PF-3644022 Potent and Selective MK2 inhibitor PF-3644022  Chemical Structure
  51. GC10689 PF-4708671

    PF-4708671, is a novel cell-permeable inhibitor of S6K1, specifically inhibits the S6K1 isoform with a Ki of 20 nM and IC50 of 160 nM.

    PF-4708671  Chemical Structure
  52. GC10261 PH-797804 P38 MAP kinase inhibitor, potent and selective PH-797804  Chemical Structure
  53. GC41635 Phosphodiesterase 4 Inhibitor Phosphodiesterase 4 (PDE4) inhibitor is an inhibitor of PDE4 with an IC50 value of 0.10 μM for the human recombinant enzyme. Phosphodiesterase 4 Inhibitor  Chemical Structure
  54. GC18050 Pimasertib (AS-703026) Pimasertib (AS-703026) (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor. Pimasertib (AS-703026)  Chemical Structure
  55. GC10282 Piperlongumine An alkaloid with anticancer and antioxidant activities Piperlongumine  Chemical Structure
  56. GC44653 PKA Inhibitor (5-24) PKA Inhibitor (5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKA Inhibitor (5-24)  Chemical Structure
  57. GC48329 PKA Inhibitor (5-24) (trifluoroacetate salt) A synthetic peptide inhibitor of PKA PKA Inhibitor (5-24) (trifluoroacetate salt)  Chemical Structure
  58. GP10075 PKA inhibitor fragment (6-22) amide

    A synthetic peptide inhibitor of PKA

    PKA inhibitor fragment (6-22) amide  Chemical Structure
  59. GC61512 PKA Inhibitor Fragment (6-22) amide TFA PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA  Chemical Structure
  60. GC49265 PKI (14-22) amide (myristoylated) (trifluoroacetate salt) A PKA inhibitor PKI (14-22) amide (myristoylated) (trifluoroacetate salt)  Chemical Structure
  61. GC69715 PKI (14-24)amide TFA

    PKI (14-24)amide TFA is an effective inhibitor of PKA. In cell cytosol, PKI (14-24)amide strongly inhibits the activity of cyclic AMP-dependent protein kinase.

    PKI (14-24)amide TFA  Chemical Structure
  62. GC12321 PKI 14-22 amide, myristoylated PKA inhibitor PKI 14-22 amide, myristoylated  Chemical Structure
  63. GC61849 PKI 14-22 amide,myristoylated TFA PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion. PKI 14-22 amide,myristoylated TFA  Chemical Structure
  64. GC17407 Pluripotin dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP Pluripotin  Chemical Structure
  65. GC14732 PLX-4720 An orally-available inhibitor of the B-raf mutant B-RafV600E PLX-4720  Chemical Structure
  66. GC62206 PLX-4720-d7 PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf. PLX-4720-d7  Chemical Structure
  67. GC10324 PLX7904 paradox-breaker RAF inhibitor, potent and selective PLX7904  Chemical Structure
  68. GC64828 PLX7922 PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines. PLX7922  Chemical Structure
  69. GC32686 PLX8394 PLX8394  Chemical Structure
  70. GN10709 Polyphyllin A Polyphyllin A  Chemical Structure
  71. GC44673 PQ-10 PQ-10 is a potent and selective inhibitor of phosphodiesterase type 10 (PDE10; Ki = 4 nM). PQ-10  Chemical Structure
  72. GC65479 PROTAC B-Raf degrader 1 PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity. PROTAC B-Raf degrader 1  Chemical Structure
  73. GN10814 Quercitrin Quercitrin  Chemical Structure
  74. GC19304 R1487 Hydrochloride R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38α. R1487 Hydrochloride  Chemical Structure
  75. GC61485 Raf inhibitor 2 Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. Raf inhibitor 2  Chemical Structure
  76. GC37068 RAF mutant-IN-1 RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively. RAF mutant-IN-1  Chemical Structure
  77. GC15818 RAF265 Multiple intracellular kinases inhibitor RAF265  Chemical Structure
  78. GC19307 RAF709 RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC50 of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively. RAF709  Chemical Structure
  79. GC62504 RAS/RAS-RAF-IN-1 RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity. RAS/RAS-RAF-IN-1  Chemical Structure
  80. GC37071 Ravoxertinib hydrochloride Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively. Ravoxertinib hydrochloride  Chemical Structure
  81. GC16872 Refametinib

    MEK 1/ MEK 2 inhibitor

    Refametinib  Chemical Structure
  82. GC37516 Refametinib R enantiomer Refametinib R enantiomer is a MEK inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC50 of 2.0-15 nM. Refametinib R enantiomer  Chemical Structure
  83. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride  Chemical Structure
  84. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate  Chemical Structure
  85. GC40213 Regorafenib-13C-d3 Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib-13C-d3  Chemical Structure
  86. GC18751 Reticulol Reticulol is an isocoumarin derivative produced by certain species of Streptomyces that inhibits cAMP phosphodiesterase (IC50 = 41 uM). Reticulol  Chemical Structure
  87. GC37522 RGB-286638 A multi-kinase inhibitor RGB-286638  Chemical Structure
  88. GC37523 RGB-286638 free base A multi-kinase inhibitor RGB-286638 free base  Chemical Structure
  89. GN10784 Rhoifolin Rhoifolin  Chemical Structure
  90. GC50502 RI-STAD 2 AKAP disruptor; selectively binds PKA-RI with high affinity and blocks its interaction with AKAP; cell permeable RI-STAD 2  Chemical Structure
  91. GC62448 Rineterkib hydrochloride Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF. Rineterkib hydrochloride  Chemical Structure
  92. GC69821 RLX-33

    RLX-33 is an effective and selective relaxin family peptide 3 (RXFP3) antagonist with blood-brain barrier permeability. It also blocks the phosphorylation of ERK1/2 induced by relaxin 3, with IC50 values for RXFP3, ERK1, and ERK2 phosphorylation being 2.36 μM, 7.82 μM, and 13.86 μM respectively. RLX-33 can block the increase in food intake induced by the RXFP3 selective agonist R3/I5 in rats. RLX-33 can be used for research on metabolic syndrome.

    RLX-33  Chemical Structure
  93. GC50294 RMM 46 MSK/RSK family kinase inhibitor RMM 46  Chemical Structure
  94. GC12141 RO4987655 MEK inhibitor RO4987655  Chemical Structure
  95. GC12406 RO5126766(CH5126766) RO5126766(CH5126766) (CH5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively). RO5126766(CH5126766)  Chemical Structure
  96. GC38609 Rotundic acid Rotundic acid, a triterpenoid obtained from I. Rotundic acid  Chemical Structure
  97. GC15611 Rp-8-Br-PET-cGMPS cGMP-dependent protein kinase (PKG) inhibitor Rp-8-Br-PET-cGMPS  Chemical Structure
  98. GC44852 Rp-8-bromo-Cyclic AMPS (sodium salt) Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP. Rp-8-bromo-Cyclic AMPS (sodium salt)  Chemical Structure
  99. GC44853 Rp-8-CPT-Cyclic AMP (sodium salt) Rp-8-CPT-Cyclic AMP (sodium salt), a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-Cyclic AMP (sodium salt)  Chemical Structure
  100. GC63176 Rp-cAMPS sodium salt Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 ?M and 4.5 ?M, respectively) antagonist. Rp-cAMPS sodium salt  Chemical Structure
  101. GC62269 RRD-251 RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities. RRD-251  Chemical Structure

Items 301 to 400 of 498 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction